



RBC Capital Markets Virtual Ophthalmology Conference

Corporate Presentation

April 2025

Legal Disclaimer

This Presentation contains forward looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Presentation, including statements regarding our clinical development plans, strategy, future operations, future financial position, prospects, plans, objectives of management, and implied and express statements regarding the therapeutic potential, clinical benefits of and market potential of our product candidates are forward looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in these forward looking statements, and you should not place undue reliance on these forward looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward looking statements. In addition, the forward looking statements included in this Presentation represent our views as of the date of this Presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward looking statements in the future, we specifically disclaim any obligation to do so. These forward looking statements should not be relied upon as representing our views as of any date subsequent to the date of this Presentation.

This Presentation discusses our product candidates that are under preclinical study and in clinical trials, and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic use for which they are being studied.

This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities.

4DMT is Officially a Phase 3 Company



4FRONT-1 

The 4FRONT-1 logo consists of the text "4FRONT-1" in a bold, blue, sans-serif font, followed by a stylized graphic of three overlapping, right-pointing chevrons in shades of blue and teal.

***FIRST PATIENTS ENROLLED AT MULTIPLE
SITES IN WET AMD PHASE 3 STUDY***

4D-150: Phase 3 Therapeutic Designed to Disrupt the Global Market for Retinal Vascular Diseases & Improve Patient Outcomes



Multi-Billion Dollar Annual Opportunity

Addresses Primary Clinical Unmet Need

Favorable Safety Profile

Ease of Clinical & Commercial Adoption

Topline Data from wet AMD Pivotal Trials in 2027

\$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept

Backbone therapy with multi-year durability:
Foundational therapy with paradigm-shifting treatment burden reduction & vision preservation

Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus (remains standard-of-care, >64M eyes treated)

Single IVT injection: Seamless integration into retina clinic practice flow and **buy & bill reimbursement model**

Readouts from both Phase 3 studies in 4FRONT global registration program **expected in H2 2027**

4D-I50: Phase 3 Therapeutic Designed to Disrupt the Global Market for Retinal Vascular Diseases & Improve Patient Outcomes



Multi-Billion Dollar Annual Opportunity

\$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept

Addresses Primary Clinical Unmet Need

Backbone therapy with multi-year durability:
Foundational therapy with paradigm-shifting treatment burden reduction & vision preservation

Favorable Safety Profile

Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus (remains standard-of-care, >64M eyes treated)


Ease of Clinical & Commercial Adoption

Single IVT injection: Seamless integration into retina clinic practice flow and buy & bill reimbursement model

Topline Data from wet AMD Pivotal Trials in 2027

Readouts from both Phase 3 studies in 4FRONT global registration program expected in H2 2027

Total Branded Anti-VEGF Market Continues to Grow with Share Driven by Incremental Durability Improvements: Aflibercept Remains Market Leader




Source: EvaluatePharma Historical and Consensus Estimates as of 3/7/2025.

Note: Product sales reflect sales across manufacturers; Eylea sales include both Eylea and Eylea HD formulations

Incremental Durability Improvements for Bolus Anti-VEGFs Have Resulted in Accelerating Launch Performance

LUCENTIS
RANIBIZUMAB INJECTION


Durability: ~30 Days¹



EYLEA[®]
(aflibercept) Injection
For Intravitreal Injection

Durability: ~44 Days²


Burden Reduction vs. Lucentis:
~32%



VABYSMO[™]
faricimab-svoa injection 6 mg

Durability: ~57 Days²

Burden Reduction vs. Eylea:
~23%



1. Lucentis package insert; 2. Real-World Evidence (TRUCKEE Study). Injection Burden Reduction vs. prior therapy implied based on difference calculated annual injections based on TRUCKEE durability.

4D-I50: Phase 3 Therapeutic Designed to Disrupt the Global Market for Retinal Vascular Diseases & Improve Patient Outcomes



Multi-Billion Dollar
Annual Opportunity

**Addresses Primary
Clinical Unmet Need**

Favorable
Safety Profile

Ease of Clinical &
Commercial
Adoption

Topline Data from
wet AMD Pivotal
Trials in 2027

\$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept

Backbone therapy with multi-year durability:
Foundational therapy with paradigm-shifting
treatment burden reduction & vision preservation

Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus
(remains standard-of-care, >64M eyes treated)

Single IVT injection: Seamless integration into retina clinic
practice flow and **buy & bill reimbursement model**

Readouts from both Phase 3 studies in 4FRONT global
registration program **expected in H2 2027**

Short Durability of Wet AMD Standard of Care Leads to Poor Vision Outcomes


Durability

Impact on Retinal Anatomy

Vision

Current
Standard of
Care

Bolus loading doses, followed by...



Associated with **greater vision loss¹** & **fibrosis²**



¹Guo et al. *Ophthalm Res* 2023; 66:406-12. ²Evans et al. *JAMA Ophthalmol* 2020;138:1043-51.

Markedly Improving Outcomes with a Multi-year Backbone Therapy

**Current
Standard of
Care**

Durability

Impact on Retinal Anatomy

Vision

Bolus loading doses, followed by...

- 4 weeks
- 4-8 weeks
- 8 weeks
- 8-12 weeks
- 8-12-16 weeks
- 8-16 weeks

Associated with **greater vision loss¹ & fibrosis²**

**Solution:
4D-I50
Backbone
Therapy**

Durability

Impact on Retinal Anatomy

Vision

Bolus loading doses, followed by...

4D-I50

Multiple
years


Goal Post-4D-I50

Bolus supplement as needed

Low retinal variability to **preserve vision**

¹Guo et al. *Ophthalm Res* 2023; 66:406-12. ²Evans et al. *JAMA Ophthalmol* 2020;138:1043-51.

4D-I50 Demonstrated Transformative Treatment Burden Reduction & Durability in Multiple Wet AMD Patient Populations



4D-I50: Phase 3 Therapeutic Designed to Disrupt the Global Market for Retinal Vascular Diseases & Improve Patient Outcomes



Multi-Billion Dollar
Annual Opportunity

\$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept

Addresses Primary
Clinical Unmet Need

Backbone therapy with multi-year durability:
Foundational therapy with paradigm-shifting
treatment burden reduction & vision preservation

**Favorable
Safety Profile**

Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus
(remains standard-of-care, >64M eyes treated)

Ease of Clinical &
Commercial
Adoption

Single IVT injection: Seamless integration into retina clinic
practice flow and **buy & bill reimbursement model**

Topline Data from
wet AMD Pivotal
Trials in 2027


Readouts from both Phase 3 studies in 4FRONT global
registration program **expected in H2 2027**

4D-150 Has Been Well Tolerated in Broad Wet AMD Population: Safety In-Line With Aflibercept Protein to Date

- No 4D-150–related serious adverse events
- No 4D-150–related hypotony, endophthalmitis, occlusive/non-occlusive retinal vasculitis, or choroidal effusions
- Treatment-related **1+** vitreous cells at a single timepoint observed in 2 of 71 (**2.8%**)
- **99%** (70 of 71) completed prophylactic topical steroid taper on schedule
- **99%** (70 of 71) remain completely off steroids

4D-150 3E10 vg/eye (N=71)*


Highest SUN/NEI Score[†]



*Duration of follow up, ≤ 3 years. [†]4D-150–related.

VC, Vitreous cell; NEI, National Eye Institute; SUN, Standardization of Uveitis Nomenclature.

4D-I50 Has Been Well Tolerated in DME Patients: No Intraocular Inflammation at Any Timepoint at Any Dose Level



- All patients completed the 16-week topical steroid taper on schedule and remained completely off steroids
- No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions

Data cutoff date, December 13, 2024. *Excludes patient with early termination due to death. The subject had a prior history of hepatic cirrhosis and died prior to any study visits due to liver failure (assessed by PI as unrelated to 4D-I50). NEI, National Eye Institute; SUN, Standardization of Uveitis Nomenclature; X, missed visit. One of the subjects missed three consecutive study visits due to recovery from foot surgery.

4D-150: Phase 3 Therapeutic Designed to Disrupt the Global Market for Retinal Vascular Diseases & Improve Patient Outcomes



Multi-Billion Dollar
Annual Opportunity

\$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept

Addresses Primary
Clinical Unmet Need

Backbone therapy with multi-year durability:
Foundational therapy with paradigm-shifting
treatment burden reduction & vision preservation

Favorable
Safety Profile

Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus
(remains standard-of-care, >64M eyes treated)

**Ease of Clinical &
Commercial
Adoption**

Single IVT injection: Seamless integration into retina clinic
practice flow and **buy & bill reimbursement model**

Topline Data from
wet AMD Pivotal
Trials in 2027

Readouts from both Phase 3 studies in 4FRONT global
registration program **expected in H2 2027**

Potential to Improve Economic Value for Payors and Clinics with 4D-I50

Payors

- **Adherence by design**, leading to long term preservation of vision
- **Reduction in treatment burden**, leading to patient freedom and quality-of-life
- **Preservation of vision**, leading to socio-economic benefit
- **Low expected COGS**, leading to pricing flexibility

Clinics

- **IVT dosing with seamlessly adoption** into current practice flow
- **Seamless integration into current distribution networks & clinic storage**
- **Improved cash flow & clinic capacity**, esp with Buy & Bill reimbursement model

4D-I50: Phase 3 Therapeutic Designed to Disrupt the Global Market for Retinal Vascular Diseases & Improve Patient Outcomes



Multi-Billion Dollar
Annual Opportunity

\$17B+ and growing global market
Leveraging expression of validated blockbuster aflibercept

Addresses Primary
Clinical Unmet Need

Backbone therapy with multi-year durability:
Foundational therapy with paradigm-shifting
treatment burden reduction & vision preservation

Favorable
Safety Profile

Predictable long-term safety:
Clinically significant IOI rate in-line with aflibercept bolus
(remains standard-of-care, >64M eyes treated)

Ease of Clinical &
Commercial
Adoption

Single IVT injection: Seamless integration into retina clinic
practice flow and **buy & bill reimbursement model**


**Topline Data from
wet AMD Pivotal
Trials in 2027**

Readouts from both Phase 3 studies in 4FRONT global
registration program **expected in H2 2027**

Global 4FRONT Phase 3 Trial Design

Noninferiority Trials to Enable Global Registration in Wet AMD

Global, Multicenter, Randomized, Double Masked, Aflibercept Q8W Comparator Controlled Studies




*Determined by SD-OCT and confirmed by an independent Reading Center. †PI discretion not allowed.

Global 4FRONT Phase 3 Trial Design


Noninferiority Trials to Enable Global Registration in Wet AMD

Global, Multicenter, Randomized, Double Masked, Aflibercept Q8W Comparator Controlled Studies



*Determined by SD-OCT and confirmed by an independent Reading Center. †PI discretion not allowed.

4D-I50 Wet AMD Phase 3 Expected Milestones



Pipeline Focused on Large Market Indications with High Unmet Need

| THERAPEUTIC AREA VECTOR ROUTE OF ADMIN | PRODUCT CANDIDATE | INDICATION | ESTIMATED PREVALENCE | PHASE 1 | PHASE 2 | PIVOTAL | STATUS |
|--|----------------------|--|-------------------------|--|---------|---------|--|
| LARGE MARKET OPHTHALMOLOGY  RI00 Intravitreal | 4D-150 | Wet AMD | ~3M U.S./EUMM |  | | | <ul style="list-style-type: none"> ✓ PRISM Ph2b 52-week interim data: Feb 10, 2025 ✓ 4FRONT-1 Initiation: Mar 2025 ▪ 4FRONT-2 Initiation: Q3 2025 ▪ PRISM Ph 1/2a 2-year & Ph2b 1.5-year data: Q4 2025 ▪ 4FRONT-1 & -2 topline data: H2 2027 |
| | | DME | ~5M U.S./EUMM |  | | | Part I: <ul style="list-style-type: none"> ✓ 32-week interim data ▪ 52-week interim data: Q3 2025 |
| PULMONOLOGY  AI01 Aerosol | 4D-710 | CF lung disease (mod. ineligible/intolerant) | ~15K WW |  | | | <ul style="list-style-type: none"> ▪ Interim data: H2 2025 |

\$505M cash as of December 31, 2024; Runway into 2028



THANK YOU

5858 Horton Street, Suite 455 | Emeryville, California 94608

(510) 505-2680 | Investor.Relations@4DMT.com

IR.4DMT.com | [LinkedIn](#)